BOLT
BOLT
NASDAQ · Biotechnology

Bolt Biotherapeutics Inc

$3.46
-0.12 (-3.35%)
As of Sep 28, 10:41 PM ET ·
Financial Highlights (FY 2026)
Revenue
7.93M
Net Income
-34,383,133
Gross Margin
—
Profit Margin
-433.7%
Rev Growth
+10.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 57.8% 57.8%
Operating Margin -469.3% -422.4% 7.8% 8.9%
Profit Margin -433.7% -412.1% 6.7% 7.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 7.93M 7.18M 3.98M 4.32M
Gross Profit — — 2.30M 2.50M
Operating Income -37,201,884 -30,346,864 310.2K 383.6K
Net Income -34,383,133 -28,047,511 267.7K 303.4K
Gross Margin — — 57.8% 57.8%
Operating Margin -469.3% -422.4% 7.8% 8.9%
Profit Margin -433.7% -412.1% 6.7% 7.0%
Rev Growth +10.3% +10.3% +11.2% +18.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 2.96M 2.24M
Total Equity — — 7.70M 8.12M
D/E Ratio — — 0.39 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -35,872,776 -30,888,368 477.9K 559.3K
Free Cash Flow — — 225.1K 222.9K